EPHOS-B
Disease site: Breast Cancer
Treatment Modality: Combination Therapy
Status: Open to recruitment
EPHOS-B is a Phase III, multicentre, three arm, randomised controlled trial in women with HER2+ early breast cancer. The primary objective of the trial is to determine whether pre-operative treatment of HER-2 positive breast cancer patients with anti HER2 therapy inhibits proliferation or increases apoptosis.
Chief Investigator: | Prof Nigel Bundred |
Sponsor: | University of Manchester/University Hospital of South Manchester NHS Foundation Trust/The Institute of Cancer Research |
Source of funding: | CRUK |
ISRCTN: | 15004993 |
In the Clinical Trials Section
